Genetic risk scores (GRSs) have been associated with coronary heart disease (CHD) in large studies. We asked whether expanding an established 27-variant GRS (GRS27) to a 50-variant GRS (GRS50) improved CHD prediction and whether GRSs are independent of self-reported family history of CHD.
Introduction
Coronary heart disease (CHD) is the leading cause of death in the European Union as well as in the USA-an estimated 1.8 million Europeans and 400 000 Americans die of CHD annually, at an estimated annual cost of E60 billion in the European Union and $108.9 billion in the USA.
1,2 Therefore, improving CHD risk prediction in order to effectively direct CHD risk prevention resources is an important public health goal. The association of established risk factors with CHD in large prospective studies has been used to develop a number of CHD risk prediction models, most recently by the European Association for Cardiovascular Prevention & Rehabilitation 3 and US American College of Cardiology/American Heart Association task force on practice guidelines. 4 Typically, these models incorporate information about age, sex, hypertension, blood cholesterol, smoking history, and history of diabetes to calculate the probability of CHD event in the short term (10 years) or long term. The heritability of CHD is well documented, 5 -7 which motivated the inclusion of family history of CHD as an option for risk assessment in patients with borderline risk. 8, 9 However, despite the identification of numerous genetic variants that are associated with CHD, 10, 11 a direct assessment of a patient's genetic risk is not typically included in accepted CHD risk prediction models. Genetic risk scores (GRSs)-based on single nucleotide polymorphisms (SNPs) associated with CHD-have been shown to be associated with future CHD events in large case -control and prospective studies. 12 -16 However, it has not been fully assessed (i) whether increasing the number of genome-wide significant (GWS) SNPs in GRS-based CHD risk prediction continue to improve risk prediction, (ii) whether GRS could improve CHD risk assessment beyond self-reported family history, and (iii) whether GRS risk differs between younger and older individuals. We investigated these questions in a large population-based prospective study of middle-aged men and women.
Methods

Study participants
The Malmö Diet and Cancer (MDC) study is a community-based, prospective observational study of 30 447 participants drawn from 230 000 residents of Malmö , Sweden. Men aged 46 -73 years and women aged 45-73 years were invited to participate and were enrolled between 1991 and 1996. 17 Details of the MDC design have been previously reported. 17, 18 The primary endpoints of the study were time to first occurrence of CHD (composite endpoint of coronary event, cardiovascular death, and revascularizations). After exclusions, 23 595 participants were included in the current study. A detailed description of the inclusion and exclusion criteria in the current study, baseline assessment, and endpoint determination are provided in the Supplemental material online.
Modelling of genetic risk score
We assessed the association of CHD with each of two GRSs (Supplementary material online, Table S1 ). One GRS is the 27-SNP GRS (GRS27) described by Mega et al. 19 A second GRS comprised the GRS27 SNPs and 23 additional SNPs, for a total of 50 SNPs (GRS50). Each of these 23 additional SNPs has been shown to be associated with CHD at a GWS level. The GRS of each individual in the current study was calculated as follows: the previously reported risk estimate for the modelled allele of each SNP (Supplementary material online, Table S1 ) was natural log transformed and multiplied by one (for heterozygotes) or two (for homozygotes); these products were then summed. The mean (2.49 for GRS27 and 3.82 for GRS50) and standard deviation (0.34 for GRS27 and 0.43 for GRS50) of the study population were used to standardize each GRS to have a mean of 0 and unit variance. 
Results
Study population and genetic risk scores
The baseline characteristics of the 23 595 MDC participants in this study are provided in Table 2) . Those with high GRS50 had 1.92-fold greater risk of CHD than those with low genetic risk (95% CI: 1.67 -2.20, P ¼ 7.5 × 10 221 ). For GRS27, those with high genetic risk had 1.7-fold greater risk of CHD than those with low genetic risk (95% CI: 1.48 -1.94). When both GRS27 and a GRS comprising the 23 SNPs present in GRS50 but not in GRS27 were included in a model that also adjusted for established risk factors, both GRS27 and GRS23 were associated with incident CHD events (P ¼ 2 × 10 213 and 3 × 10 26 , respectively). That is, CHD risk prediction by a model that included GRS27 was improved by adding 23 additional SNPs.
Discrimination and reclassification
27-Variant genetic risk score and GRS50 each improved the discrimination of a model that included established risk factors even after adding self-reported family history (P ≤ 2 × 10 216 ) although the magnitude of the improvement of c-statistic was modest (Supplementary material online, Table S3 ). Self-reported family history improved discrimination of an established risk factors model. Risk classification by a model that included established risk factors and self-reported family history was improved by both GRS27 [continuous net reclassification improvement index (cNRI) ¼ 0.15, P , 0.0001, 7% in those without events and 8% in those with events, Supplementary material online, Table S4 ] and GRS50 (cNRI ¼ 0.17, P , 0.0001, 10% in those without events and 7% in those with events). Risk classification of an established risk factor model was also improved by self-reported family history, although among patients with events, more patients were reclassified in the wrong direction (lower risk). Risk classification was not improved by GRS27 and GRS50 in a categorical analysis (above and below 7.5% 10-year risk categories 4 ; Supplementary material online, Table S5 ).
Genetic risk scores and self-reported family history 27-Variant genetic risk score and GRS50 were associated with incident CHD events in participants with and without self-reported family history. In a stratified analysis that adjusted for established risk factors, the HR for CHD for a high compared with a low GRS50 was 1. analysis of the combined strata, the P for interaction was 0.33 in a model that adjusted for established risk factors and included a term for the interaction between family history and GRS50. Selfreported family history was associated with incident CHD events after adjustment for established risk factors (HR ¼ 1.43, 95% CI: 1.31 -1.56, P ¼ 8 × 10 217 ). Adjustment for self-reported family history in the combined strata did not appreciably change these risk estimates (HR ¼ 1.87; 95% CI: 1.63-2.14 for GRS50 and HR ¼ 1.40; 95% CI: 1.29 -1.53 for family history). Similar results were observed for GRS27 (Table 3) . Both GRS27 and GRS50 were associated with self-reported family history of CHD (P , 0.0001); the odds of a positive self-reported family history among those with high GRS compared with having low GRS were modest; OR ¼ 1.37 (95% CI: 1.26-1.49) for GRS27 and OR ¼ 1.40 (95% CI: 1.29 -1.53) for GRS50. The GRS distribution among participants with and without self-reported family history is shown in Supplementary material online, Figure S2 .
Genetic risk score in young and old
Since genetic risk is generally thought to be more important in young individuals, we investigated the interaction between age and GRS and found that the CHD risk associated with GRS varied with age for both GRS27 and GRS50 (P interaction ¼ 0.03 for both). We further assessed the GRS in those below and above the median age of this study (57.6) and found that risk associated with either GRS50 or GRS27 differed among those below and above the median age (P interaction , 0.003) in models that adjusted for established risk factors (Table 4 and Supplementary material online, Table S6 for event rate by GRS category and age category). Among the young, those with high GRS had more than two-fold greater risk of CHD than those with low GRS (HR ¼ 2.40; 95% CI: 1.84 -3.12; P ¼ 7.5 × 10 211 for GRS50 and HR ¼ 2.24; 95% CI: 1.72 -2.90; P ¼
× 10
29 for GRS27). We examined the event rate in those with and without self-reported family history of CHD according to their GRS status ( Figure 1) . We found that in the young, the cumulative incidence in the presence of competing risk among those with high GRS50 without a self-reported family history (0.065 at Year 15) was greater than the cumulative incidence among those with low GRS50 with a self-reported family history (0.041, P ¼ 0.013 for Gray test; Figure 1A ). Similar trends (0.153 and 0.128, P ¼ 0.094) were also observed in those above the median age (Panel B). Similar results were observed for GRS27 (Supplementary material online, Figure S3 ). We also examined whether CHD risk prediction by GRS varied by sex and found no evidence for interaction between sex and GRS (P interaction . 0.3).
Discussion
In a large community-based prospective study of 23 595 participants, we investigated a 27-SNP and a 50-SNP GRS for CHD and found that CHD risk assessed by both GRS is independent of selfreported family history, and for both the 27-SNP and the 50-SNP GRS, the associated CHD risk estimates were higher among younger individuals than among older individuals.
Genetic risk scores comprising SNPs that are individually associated with CHD at a GWS level have been investigated previously. In 2010, Ripatti et al. 12 reported that GRS comprising 13 SNPs was associated with incident CHD in several cohorts; however, this 13-SNP GRS did not improve net reclassification when added to established traditional risk factors. Following the publication of the largest to date meta-analysis genome-wide association in 2013, 11 Andrea et al. 13 investigated a 46-SNP GRS in six Swedish studies comprising 10 000 individuals and found that this 46-SNP GRS improved net reclassification when added to established risk factors. More recently, Mega et al. 19 investigated a 27-SNP GRS in randomized, placebo-controlled studies of statin therapy and found that the 27-SNP GRS could identify individuals who would benefit from statin therapy.
Since the risk associated with each individual SNP is modest, and since SNPs that have been only identified in recent large studies typically have risk estimates that are lower than SNPs that were identified in smaller, earlier studies, it was unclear whether it would be useful to include these more recently identified SNPs in a GRS. Our study investigated this question directly. We showed a model that includes 23 SNPs in addition to those in the previously reported 27-SNP GRS improves risk prediction. However, adding either GRS27 or GRS50 to established risk factors resulted in similar improvement in discrimination (c-statistic) and reclassification (cNRI).
Our study also found that subjective, self-reported family history of CHD and objectively measured genetic risk are not redundant. 20 Both can contribute to a better assessment of a patient's CHD risk because a GRS-based genetic risk measure is associated with CHD independent of self-reported family history of CHD, as well as established risk factors, that is, self-reported family history is not a substitute for genetic risk assessment. Since family history reflects both genetic and non-genetic factors, and since the accuracy of patientreported family history is low, this non-redundancy of self-reported family history and genetic assessment is not surprising.
Since genetics is generally thought to play a more important role in CHD events that occur in younger individuals than in older individuals, we examined the 27-SNP and 50-SNP GRS risk estimates in different age groups and found that those risk estimates were higher in younger individuals than in older individuals. Moreover, younger individuals with no self-reported family history of CHD and with high GRS had greater risk than those with self-reported family history of CHD and a low GRS. This finding suggests that a GRS-based risk assessment could be particularly useful among younger individuals. The potential for a point-of-care GRS testing in routine clinical practice makes genetic testing among younger individualsparticularly those with borderline CHD risk by established risk factors-attractive since it could overcome barriers faced by other predictive tools, e.g. 24 h ambulatory blood pressure monitoring.
Our study has several limitations. This study was conducted in Swedish middle-aged individuals; hence, the generalizability to other ethnicities or age groups is uncertain. LDL cholesterol and HDL cholesterol levels were not available for our study population; therefore, we used the available apoA-I and apoB plasma levels as Figure 1 Cumulative incidence of coronary heart disease events according to self-reported family history of coronary heart disease and 50-variant genetic risk score. Blue and green: those with high 50-variant genetic risk score with (blue) or without (green) a selfreported family history. Red and black: those with low 50-variant genetic risk score with (red) or without (black) a self-reported family history. Inset: those with intermediate 50-variant genetic risk score with (dashed) or without (dotted) a self-reported family history. FH, self-reported family history. Cumulative incidence was estimated while considering non-coronary heart disease death as competing risk. (A) Participants younger than median age (≤57.6). Median age for this younger group is 51.4 (interquartile range, 48.8-54.2). (B) Participants older than median age (.57.6). Median age for this older group is 64.7 (interquartile range, 61.1-67.7).
covariates in our established risk factors model. A different definition of self-reported family history might have produced different results. For example, the definition of self-reported family history of CHD in the Framingham Heart Study considers only CHD family member events that occurred before age 55 for men or 65 for women. However, in clinical practice, patients may not know the age at which their family member had a CHD event or may not be asked about the age. For these reasons, the family history question asked at baseline in MDC did not specify any limitations on the age of the family member at the time of event. The fraction of women in MDC is greater than that in other European-based population studies. 11 However, since we found no interaction between GRS and sex, we believe that our results should be generalizable to populations with different proportion of women. Although our results suggest that genetic risk assessment could be useful in the young, this study population did not include sufficient number of individuals to provide risk estimates in those ,45 years of age. Additional studies would be needed to address this question.
In conclusion, a GRS could improve risk assessment for future CHD when added to established risk factor models. We suggest that such genetic assessment could be considered for individuals whose established risk-based treatment decision is uncertain.
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Supplementary material is available at European Heart Journal online. 
